$5.840
0.000 (0.00%)Zum Schluss
- Hoch
- 5.860
- Eröffnung
- 5.840
- Volumengewichteter Durchschnittskurs
- 5.85
- Volumen
- 753.60K
- Marktkap.
- —
- Tief
- 5.840
- Umsatz
- 4.41M
- EV/EBITDA, TTM
- -20.09
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Analystenbewertungen (10)
Canaccord Genuity
$5.85
2025-02-07
Canaccord Genuity
2025-02-07
Kursziel
$5.85
Piper Sandler
$5.85
2025-02-07
Piper Sandler
2025-02-07
Kursziel
$5.85
Truist Securities
$4.7
2024-12-18
Truist Securities
2024-12-18
Kursziel
$4.7
Wells Fargo
$4
2024-12-11
Wells Fargo
2024-12-11
Kursziel
$4
Citigroup
$5
2024-12-11
Citigroup
2024-12-11
Kursziel
$5
Bewertungskennzahlen
Event-Zeitleiste
News
5.008-04GlobenewswireNVRO Metals Appoints New Technical Advisor to Board
7.507-08Yahoo FinanceNVRO Metals Signs Initial Agreement with Hecla Subsidiary
6.002-15Yahoo FinanceGlobus Medical Upgraded to Buy by Needham with $112 Target
7.501-21GlobenewswireEnviroGold's NVRO Process Advances to Expand Market Potential
8.501-13GlobenewswireEnviroGold Hosts Investor Webinar on Metal Recovery Opportunities
NVRO FAQ – beantwortet von Alphio AI
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
10 analysts cover NVRO: 10 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.85.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.